Vicor Technologies, Inc.'s PD2i(R) Nonlinear Algorithm Selected for Use in Screening Initiative to Identify Youth at Risk of Sudden Cardiac Death

BOCA RATON, FL--(Marketwire - December 10, 2009) - David H. Fater, CEO of Vicor Technologies, Inc. (OTCBB: VCRT), today announced that its PD2i® nonlinear algorithm has been selected by Dr. Sanjay Sharma to be used in a month-long cardiac screening initiative to be held in South East London in April 2010. Vicor Technologies is a biotechnology company focused on the commercialization of innovative, non-invasive medical devices and diagnostics using its patented, proprietary PD2i® nonlinear algorithm and software to stratify patients at risk of sudden cardiac death or autonomic dysfunction, and trauma victims in need of lifesaving intervention.

Dr. Sharma, consultant cardiologist of Cardiac Risk in the Young (CRY), is spearheading the screening initiative which will offer free cardiac screening to 14 year olds (DOB 1995) living in South East London; 14 is the earliest post-puberty age for which proactive screening is considered viable. Ten percent of the estimated seven million individuals fitting this description are expected to participate. Vicor’s PD2i® nonlinear algorithm will be used along with ECG and echocardiogram to identify participants at risk of sudden cardiac death.

“The ultimate goal of this initiative is to develop a prototype for a national screening program for young sudden cardiac death, which is an extremely worthy goal, given that some 600 young people are struck down by sudden cardiac death annually in the U.K. We’re honored to have our PD2i® nonlinear algorithm selected for use in this important initiative,” stated Dr. Daniel Weiss, cardiologist and Vicor’s Chief Medical Officer.

“Given the consistently accurate results achieved with the PD2i® nonlinear algorithm in risk stratifying adults at risk of sudden cardiac death, we’re confident that the PD2i® nonlinear algorithm will prove beneficial in identifying 14 year olds participating in the initiative, who will then be able to obtain effective treatment,” stated Mr. Fater.

Dr. Sharma was recently-appointed Professor of the newly-created Inherited Cardiovascular Disease and Sports Cardiology Centre at St. George’s Healthcare NHS Trust. He will begin his tenure in February 2010. The Inherited Cardiovascular Disease and Sports Cardiology Centre is the world’s first specialist, multi-disciplinary facility dedicated to providing services to populations affected by or at risk for (including families and athletes) young (14-35) sudden cardiac death. St. George’s is one of England’s largest teaching hospitals and the first hospital in the United Kingdom to develop a specialist clinic for young sudden cardiac death after receiving CRY’s donation of echocardiogram equipment. CRY was founded in 1996 to raise awareness of conditions that can lead to sudden cardiac death and sudden cardiac death syndrome in those between the ages of 14 and 35.

About Vicor Technologies, Inc.

Vicor Technologies is a development-stage biotechnology company creating innovative non-invasive diagnostics employing its patented, proprietary point correlation dimension algorithm (PD2i®). The PD2i® nonlinear algorithm is a deterministic, nonlinear measure of electrophysiological potentials to predict future pathological events with a high degree of accuracy in target populations.

Vicor currently has three products employing the PD2i® nonlinear algorithm. The PD2i Analyzer™, which has FDA 510(k) marketing clearance, measures heart rate variability; physicians performing diagnostic tests with the PD2i Analyzer™ are able to receive reimbursement under existing CPT codes. The PD2i VS™ (Vital Sign), in clinical trials under a collaborative effort with the U.S. Army Institute for Surgical Research (http://www.usaisr.amedd.army.mil/), risk stratifies combat and civilian trauma victims. The PD2i CA™ (Cardiac Analyzer), in multiple clinical trials, identifies patients at risk of sudden cardiac death.

Vicor anticipates additional applications employing the PD2i® nonlinear algorithm to enable early detection and risk stratification for a variety of other disorders and diseases. Additional information is available at www.vicortech.com.

The appearance of name-brand institutions or products in this media release does not constitute endorsement by the U.S. Army Medical Research and Materiel Command, the Department of the Army, Department of Defense or the U.S. Government of the information, products or services contained therein.

Caution Regarding Forward-Looking Statements

Forward-looking statements in this press release are based on current plans and expectations that are subject to uncertainties and risks, which could cause our future results to differ materially. The following factors, among others, could cause our actual results to differ: our ability to obtain FDA approval of the PD2i VS™ (Vital Sign) for military and civilian applications and the PD2i CA™(Cardiac Analyzer), our ability to continue to receive financing sufficient to continue operations and complete the critical clinical trials; our ability to continue as a going concern; our ability to successfully develop products based on our technologies, included but not limited to our ASP distribution model for the PD2i Analyzer™; our ability to obtain and maintain adequate levels of third-party reimbursement for our products; the impact of competitive products and pricing; our ability to receive regulatory approval for our products; the ability of third-party contract research organizations to perform preclinical testing and clinical trials for our technologies; the ability of third-party manufacturers to manufacture our products; our ability to retain the services of our key personnel; our ability to market and sell our products successfully; our ability to protect our intellectual property; product liability; changes in federal income tax laws and regulations; general market conditions in the medical device and pharmaceutical industries; and other matters that are described in Vicor’s Annual Report on Form 10-K for the fiscal year ended December 31, 2008 and subsequent filings with the Securities and Exchange Commission. Forward-looking statements in this press release speak only as of the date of the press release, and we assume no obligation to update forward-looking statements or the reasons why actual results could differ.

Release 09-24

Digg this Bookmark with del.icio.us Add to Newsvine

Technorati: cardiac risk in the young sudden cardiac death biotech medical devices diagnostics cardiology